Literature DB >> 18374782

Native lung volume reduction surgery relieves functional graft compression after single-lung transplantation for chronic obstructive pulmonary disease.

T Brett Reece1, John D Mitchell, Martin R Zamora, David A Fullerton, Joseph C Cleveland, Marvin Pomerantz, Dennis M Lyu, Frederick L Grover, Michael J Weyant.   

Abstract

OBJECTIVE: Single-lung transplantation is an accepted treatment for end-stage lung disease caused by chronic obstructive pulmonary disease. A complication unique to single-lung transplantation for chronic obstructive pulmonary disease is graft dysfunction due to compression caused by native lung hyperinflation. We hypothesized that patients with functional compromise from native lung hyperinflation would benefit from native lung volume reduction surgery.
METHODS: The charts of all patients undergoing single-lung transplantation for chronic obstructive pulmonary disease were reviewed for lung volume reduction surgery of their native lung. Data regarding length of stay, surgical morbidity and mortality, overall survival, type of lung volume reduction surgery, and pulmonary function were recorded to evaluate the effect of lung volume reduction surgery.
RESULTS: Between February 1992 and May 2007, 206 single-lung transplantations were performed for chronic obstructive pulmonary disease. Ten (5%) patients had clinically significant graft compression from native lung hyperinflation. After excluding other causes for functional decline, these patients underwent a modified lung volume reduction surgery between 12 and 142 months after single-lung transplantation (mean, 50 months). Lung volume reduction surgery consisted of anatomic resection. Two (20%) of 10 patients died during their hospitalization. Of the remaining 8 patients, 7 (87.5%) have demonstrated functional improvement on the basis of forced expiratory volume in 1 second improving from 12% to 200% (mean improvement, 57%). Within 6 months of lung volume reduction surgery, mean 6-minute walk values improved significantly (866 to 1055 feet), whereas desaturation with exertion decreased significantly.
CONCLUSIONS: Lung volume reduction surgery by means of formal lobectomy in patients with native lung hyperinflation undergoing single-lung transplantation and significant graft compression appears feasible. Additionally, improvements in forced expiratory volume in 1 second can be accomplished in nearly all properly selected patients. Lung volume reduction surgery should be considered in patients with decreasing graft function caused by graft compression from native lung hyperinflation.

Entities:  

Mesh:

Year:  2008        PMID: 18374782     DOI: 10.1016/j.jtcvs.2007.10.069

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Single-lung transplantation in emphysema: Retrospective study analyzing survival and waiting list mortality.

Authors:  José M Borro; María Delgado; Elisabeth Coll; Salvador Pita
Journal:  World J Transplant       Date:  2016-06-24

Review 2.  Lung transplantation in advanced COPD: is it worth it?

Authors:  Jamie L Todd; Scott M Palmer
Journal:  Semin Respir Crit Care Med       Date:  2010-05-21       Impact factor: 3.119

Review 3.  Lung volume reduction followed by lung transplantation-considerations on selection criteria and outcome.

Authors:  Alexis Slama; Christian Taube; Markus Kamler; Clemens Aigner
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 4.  Postoperative Management of Hyperinflated Native Lung in Single-Lung Transplant Recipients with Chronic Obstructive Pulmonary Disease: A Review Article.

Authors:  Islam M Shehata; Amir Elhassan; Ivan Urits; Omar Viswanath; Leonardo Seoane; Courtney Shappley; Alan D Kaye
Journal:  Pulm Ther       Date:  2020-12-02

5.  A proof-of principal study using phase-contrast imaging for the detection of large airway pathologies after lung transplantation.

Authors:  Stephan Umkehrer; Carmela Morrone; Julien Dinkel; Laura Aigner; Maximilian F Reiser; Julia Herzen; Ali Ö Yildirim; Franz Pfeiffer; Katharina Hellbach
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.